Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057630 | 0.87 | P2RX3 (0.42) | L3MBTL1POLBTP53 | |
| SCHEMBL18057643 | 0.86 | JAK3 (0.36) | ALDH1A1KDM4EHSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL18057644 | 0.76 | IDH1 (0.40) | LMNA | |
| SCHEMBL18327615 | 0.74 | JAK3 (0.36) | HTTKMT2AL3MBTL1GAAMEN1 | |
| SCHEMBL18057629 | 0.73 | ADORA3 (0.43) | SMN1; SMN2KMT2AL3MBTL1RECQLMEN1 | |
| SCHEMBL18057637 | 0.72 | HTT (0.48) | PKMALDH1A1KDM4EHPGDHTT | |
| SCHEMBL18057628 | 0.70 | NPSR1 (0.53) | PKMALDH1A1KDM4EHPGDHTT | |
| SCHEMBL15558065 | 0.69 | DHODH (0.48) | ALDH1A1HPGDSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL18057638 | 0.69 | KMT2A (0.50) | PKMALDH1A1KDM4EHPGDHTT | |
| SCHEMBL15535439 | 0.67 | KMT2A (0.45) | PKMALDH1A1KDM4EHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160367557-A1 | HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH | 2016-12-22 | — | — | US | disclosed |
| US-20160367557-A1 | HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH | 2016-12-22 | — | — | US | disclosed |
| US-20160362423-A1 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-12-15 | — | — | US | disclosed |
| US-20160362423-A1 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-12-15 | — | — | US | disclosed |
| US-9434745-B2 | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-09-06 | — | — | US | disclosed |
| US-9434745-B2 | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-09-06 | — | — | US | disclosed |
| EP-2861232-A1 | 7-OXO-4,7 -DIHYDRO- PYRAZOLO [1, 5 -A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | Savira Pharmaceuticals GmbH (AT) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013174931-A1 | 7-OXO-4,7 -DIHYDRO- PYRAZOLO [1, 5 -A] PYRIMIDINE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362423-A1 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | CA7, TLR7, ALAD | PKM 1524/4885ALDH1A1 622/4885KDM4E 3982/4885 |
| US-20160367557-A1 | HETEROCYCLIC PYRIMIDINE CARBONIC ACID DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | ALAD, XDH, UACA | PKM 922/4885ALDH1A1 776/4885KDM4E 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.